Rockwell Medical, Inc. (RMTI)
Chart Events
Performance Outlook
| Previous Close | 1.4450 |
| Open | 1.4000 |
| Bid | 1.4000 x 1400 |
| Ask | 1.5400 x 1000 |
| Day's Range | 1.4000 - 1.5199 |
| 52 Week Range | 0.8400 - 5.5000 |
| Volume | |
| Avg. Volume | 108,698 |
| Market Cap | 140.01M |
| Beta (5Y Monthly) | 1.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4080 |
| Earnings Date | Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
- Business Wire
Rockwell Medical Begins Selling its Hemodialysis Concentrates Products to New Clinics in Minnesota with its Largest Customer
WIXOM, Mich., December 13, 2022--Rockwell Medical, Inc. ("Rockwell" or the "Company") (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, announced that the Company is adding new business within the Minnesota region. Rockwell started to supply these clinics with its hemodialysis concentrates products effective December 5, 2022, anticipates that all clinics will be onboar
- Simply Wall St.
Rockwell Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Rockwell Medical ( NASDAQ:RMTI ) Third Quarter 2022 Results Key Financial Results Revenue: US$18.7m (up 17% from 3Q...
- Business Wire
Rockwell Medical Provides Business Strategy Update and Announces Third Quarter 2022 Financial and Operational Results
WIXOM, Mich., November 14, 2022--Rockwell Medical, Inc. ("Rockwell" or the "Company") (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today provided an update on its overall business strategy and announced its financial and operational results for the third quarter ended September 30, 2022.
